These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19536315)

  • 1. Onset of action and seizure control in Lennox-Gaustaut syndrome: focus on rufinamide.
    Saneto RP; Anderson GD
    Ther Clin Risk Manag; 2009 Apr; 5(2):271-80. PubMed ID: 19536315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.
    Glauser T; Kluger G; Sachdeo R; Krauss G; Perdomo C; Arroyo S
    Neurology; 2008 May; 70(21):1950-8. PubMed ID: 18401024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox Gastaut syndrome: A systematic review and Meta-analysis.
    Sharawat IK; Panda PK; Panda P; Dawman L
    Seizure; 2021 Oct; 91():296-307. PubMed ID: 34273668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide.
    Stafstrom CE
    Neuropsychiatr Dis Treat; 2009; 5():547-51. PubMed ID: 19898669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rufinamide for the treatment of Lennox-Gastaut syndrome.
    Besag FM
    Expert Opin Pharmacother; 2011 Apr; 12(5):801-6. PubMed ID: 21348771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of rufinamide in children and adults with Lennox-Gastaut syndrome: A post hoc analysis from Study 022.
    Arzimanoglou A; Pringsheim M; Kluger GJ; Genton P; Perdomo C; Malhotra M
    Epilepsy Behav; 2021 Sep; 124():108275. PubMed ID: 34509883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-resistant Lennox-Gastaut syndrome: therapeutic trends, challenges and future directions.
    Ostendorf AP; Ng YT
    Neuropsychiatr Dis Treat; 2017; 13():1131-1140. PubMed ID: 28461749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome.
    Wisniewski CS
    Ann Pharmacother; 2010 Apr; 44(4):658-67. PubMed ID: 20233912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial.
    Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K
    Epilepsy Res; 2016 Mar; 121():1-7. PubMed ID: 26827266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice.
    Striano P; McMurray R; Santamarina E; Falip M
    Epileptic Disord; 2018 Feb; 20(1):13-29. PubMed ID: 29313492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel seizure outcomes in patients with Lennox-Gastaut syndrome: Post hoc analysis of seizure-free days in rufinamide Study 303.
    Auvin S; Williams B; McMurray R; Kumar D; Perdomo C; Malhotra M
    Epilepsia Open; 2019 Jun; 4(2):275-280. PubMed ID: 31168494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rufinamide efficacy and association with phenotype and genotype in children with intractable epilepsy: A retrospective single center study.
    Oesch G; Bozarth XL
    Epilepsy Res; 2020 Dec; 168():106211. PubMed ID: 31575436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome.
    Coppola G; Grosso S; Franzoni E; Veggiotti P; Zamponi N; Parisi P; Spalice A; Habetswallner F; Fels A; Verrotti A; D'Aniello A; Mangano S; Balestri A; Curatolo P; Pascotto A
    Eur J Neurol; 2011 Feb; 18(2):246-251. PubMed ID: 20666837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan.
    Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K
    Epilepsy Res; 2014 Nov; 108(9):1627-36. PubMed ID: 25219353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox-Gastaut syndrome: A study of 34 patients.
    Caraballo RH; Pociecha J; Reyes G; Espeche A; Galichio S; Fasulo L; Semprino M
    Epilepsy Behav; 2020 Jul; 108():107074. PubMed ID: 32334364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
    Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Adults with Lennox-Gastaut Syndrome: Further Analysis of Efficacy and Safety/Tolerability of Rufinamide.
    McMurray R; Striano P
    Neurol Ther; 2016 Jun; 5(1):35-43. PubMed ID: 26861566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggravation of atonic seizures by rufinamide: A case report.
    Bektaş G; Çalışkan M; Aydın A; Pembegül Yıldız E; Tatlı B; Aydınlı N; Özmen M
    Brain Dev; 2016 Aug; 38(7):654-7. PubMed ID: 26906013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rufinamide efficacy and safety in children aged 1-4 years with Lennox-Gastaut syndrome.
    Kim SH; Kang HC; Lee JS; Kim HD
    Brain Dev; 2018 Nov; 40(10):897-903. PubMed ID: 30166208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.